SLC5A2 and type 2 diabetes mellitus: <b>Background/Objectives:</b> Older adults with type 2 diabetes frequently have cardiovascular or kidney disease, and current guidelines strongly recommend the use of SGLT2 inhibitors or GLP-1 receptor agonists in these high-risk populations.